These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34219153)

  • 1. Sotorasib.
    Am J Health Syst Pharm; 2021 Sep; 78(18):1656-1657. PubMed ID: 34219153
    [No Abstract]   [Full Text] [Related]  

  • 2. Sotorasib effective in KRAS-mutant NSCLC.
    Sidaway P
    Nat Rev Clin Oncol; 2021 Aug; 18(8):470. PubMed ID: 34140669
    [No Abstract]   [Full Text] [Related]  

  • 3. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
    Soulières D; Gelmon KA
    J Clin Oncol; 2021 Nov; 39(31):3427-3429. PubMed ID: 34543060
    [No Abstract]   [Full Text] [Related]  

  • 4. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain Mural Cells Express CAR T-cell Target.
    Cancer Discov; 2020 Dec; 10(12):1781-1782. PubMed ID: 33097477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotorasib (Lumakras) for NSCLC.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e104-e105. PubMed ID: 37339098
    [No Abstract]   [Full Text] [Related]  

  • 7. Distribution of
    Nassar AH; Adib E; Kwiatkowski DJ
    N Engl J Med; 2021 Jan; 384(2):185-187. PubMed ID: 33497555
    [No Abstract]   [Full Text] [Related]  

  • 8. Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
    Retmana IA; Loos NHC; Schinkel AH; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122718. PubMed ID: 33957355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMG 510 Shows Activity beyond NSCLC.
    Cancer Discov; 2020 Aug; 10(8):1084-1085. PubMed ID: 32540954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype.
    Fojo T; LaRose M; Bates SE
    Oncologist; 2024 Apr; 29(4):275-277. PubMed ID: 38498045
    [No Abstract]   [Full Text] [Related]  

  • 12. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS
    Werner JA; Davies R; Wahlstrom J; Dahal UP; Jiang M; Stauber J; David B; Siska W; Thomas B; Ishida K; Humphreys WG; Lipford JR; Monticello TM
    Toxicol Appl Pharmacol; 2021 Jul; 423():115578. PubMed ID: 34004237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
    Ratain MJ; Tannock IF; Lichter AS
    J Clin Oncol; 2021 Nov; 39(31):3423-3426. PubMed ID: 34543056
    [No Abstract]   [Full Text] [Related]  

  • 14. Olmutinib-induced palmoplantar keratoderma.
    Chen KL; Cho YT; Yang CW; Sheen YS; Liang CW; Lacouture ME; Chu CY
    Br J Dermatol; 2018 Feb; 178(2):e129-e131. PubMed ID: 28869782
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in the battle against lung tumour resistance.
    Furlow B
    Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524
    [No Abstract]   [Full Text] [Related]  

  • 16. [Advances in the molecular target therapy in lung cancer].
    Lu S; Yu YF; Li Zi
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):701-4. PubMed ID: 16438897
    [No Abstract]   [Full Text] [Related]  

  • 17. Research unveils the 'who' and 'why' of gefitinib.
    Vastag B
    J Natl Cancer Inst; 2004 Sep; 96(18):1352-4. PubMed ID: 15367564
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
    Wright KM
    Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 20. After decades, progress against an 'undruggable' cancer target.
    Kaiser J
    Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.